Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Elona Saraci
Observed names:
E Saraci,
E. Saraci,
Saraci E
Institutions:
Azienda Ospedaliera Citta' della Salute e della Scienza di Torino,
University of Turin
Observed institutions:
Azienda Ospedaliera Citta' della Salute e della Scienza di Torino,
Fondazione Gimema Onlus,
University of Turin
ORCID:
0000-0002-2275-9654
Observed ORCID:
0000-0002-2275-9654
OpenAlex ID:
A5080278478
Minimal Residual Disease Detection by Droplet Digital PCR in Multiple Myeloma, Mantle Cell Lymphoma, and Follicular Lymphoma
2015
·
Daniela Drandi
, Lenka Kubiczkova-Besse
, et al.
·
Journal of Molecular Diagnostics
·
144
PDF
Anergic bone marrow Vγ9Vδ2 T cells as early and long-lasting markers of PD-1-targetable microenvironment-induced immune suppression in human myeloma
2015
·
Barbara Castella
, Myriam Foglietta
, et al.
·
OncoImmunology
·
78
PDF
Multiple myeloma: New surface antigens for the characterization of plasma cells in the era of novel agents
2015
·
Vittorio Emanuele Muccio
, Elona Saraci
, et al.
·
Cytometry Part B Clinical Cytometry
·
65
PDF
Minimal residual disease by flow cytometry and allelic‐specific oligonucleotide real‐time quantitative polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: A pooled analysis
2018
·
Manuela Gambella
, Paola Omedé
, et al.
·
Cancer
·
41
PDF
Minimal residual disease after transplantation or lenalidomide-based consolidation in myeloma patients: a prospective analysis
2016
·
Stefania Oliva
, Manuela Gambella
, et al.
·
Oncotarget
·
38
PDF
Genomic and immune determinants of resistance to daratumumab-based therapy in relapsed refractory multiple myeloma
2024
·
Bachisio Ziccheddu
, Claudia Giannotta
, et al.
·
Blood Cancer Journal
·
35
Prospective evaluation of minimal residual disease in the phase II FORTE trial: a head-to-head comparison between multiparameter flow cytometry and next-generation sequencing
2023
·
Stefania Oliva
, Elisa Genuardi
, et al.
·
EClinicalMedicine
·
34
PDF
The bone marrow NK-cell profile predicts MRD negativity in patients with multiple myeloma treated with daratumumab-based therapy
2025
·
Charlotte L. B. M. Korst
, Sabrin Tahri
, et al.
·
Blood
·
22
Reduced Dose-Intensity Subcutaneous Bortezomib Plus Prednisone (VP) Or Plus Cyclophosfamide (VCP) Or Plus Melphalan (VMP) For Newly Diagnosed Multiple Myeloma Patients Older Than 75 Years Of Age
2013
·
Alessandra Larocca
, Federica Cavallo
, et al.
·
Blood
·
22
A longitudinal analysis of chromosomal abnormalities in disease progression from MGUS/SMM to newly diagnosed and relapsed multiple myeloma
2021
·
Stefania Oliva
, Lorenzo De Paoli
, et al.
·
Annals of Hematology
·
15
PDF
Relevance of sample preparation for flow cytometry
2017
·
V. E. Muccio
, E. Saraci
, et al.
·
International Journal of Laboratory Hematology
·
13
PDF
Targeted locus amplification to detect molecular markers in mantle cell and follicular lymphoma
2021
·
Elisa Genuardi
, Petra Klous
, et al.
·
Hematological Oncology
·
8
PDF
Regulation of B-Cell-Activating Factor Expression on the Basophil Membrane of Allergic Patients
2015
·
Monica Boita
, Enrico Heffler
, et al.
·
International Archives of Allergy and Immunology
·
8
PDF
Cardio-vascular Toxicity in Newly Diagnosed, Transplant-ineligible Multiple Myeloma Patients Treated With Carfilzomib, Cyclophosphamide and Dexamethasone: Results From an Integrated Analysis of 3 Phase I/II Trials
2017
·
Roberto Mina
, Maria Teresa Petrucci
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
·
5
Tumor Circulating Plasma Cells Detected By Flow Cytometric Single Platform Method Correlate with Clinical Response to Therapy and Unfavorable Patients' Characteristics
2019
·
Vittorio Emanuele Muccio
, Milena Gilestro
, et al.
·
Blood
·
4
Undetectable Minimal Residual Disease in Multiple Myeloma: Bridging the Gap Between Clinical Trials and Real-life Application
2025
·
Roberto Mina
, Elisabetta Antonioli
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
·
3
Single-cell transcriptomic analysis of NK cell dynamics in myeloma patients reveal persistent reduction of cytotoxic NK cells from diagnosis to relapse
2023
·
Sabrin Tahri
, Madelon M.E. de Jong
, et al.
·
bioRxiv (Cold Spring Harbor Laboratory)
·
3
PDF
Long-Term Thymic Function and Reconstitution of the T Cell Compartment after T Cell-Replete Haplo-Identical Allografting
2019
·
Giuseppe Lia
, Sara Butera
, et al.
·
Transplantation and Cellular Therapy
·
3
PDF
Improved Igh-Based MRD Detection By Using Droplet Digital PCR: a Comparison With Real Time Quantitative PCR In MCL and MM
2013
·
Daniela Drandi
, Lenka Kubiczkovà
, et al.
·
Blood
·
3
Single-Cell Transcriptomic Analysis Reveals Reduction of Cytotoxic NK Cells in a Subset of Newly Diagnosed Multiple Myeloma Patients Impacting Outcome after Daratumumab Therapy
2022
·
Sabrin Tahri
, Madelon M.E. de Jong
, et al.
·
Blood
·
2
OAB-029: Single-cell transcriptomic analysis reveals reduction of cytotoxic NK cells in a subset of newly diagnosed multiple myeloma patients impacting outcome after daratumumab therapy
2022
·
Sabrin Tahri
, Madelon de Jong
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
·
2
PDF
Predictive Model of Early Relapse in Newly Diagnosed Multiple Myeloma: Analysis from a Pooled Dataset
2019
·
Gian Maria Zaccaria
, Andrea Capra
, et al.
·
Blood
·
2
Minimal Residual Disease Detection By Multiparametric Flow Cytometry in Newly Diagnosed Multiple Myeloma Patients: A Preliminary Analysis of the EMN02/HO95 MM Study
2015
·
Stefania Oliva
, Manuela Gambella
, et al.
·
Blood
·
2
Impact of sustained MRD negativity for up to 5 years on long-term outcome of transplant-eligible newly diagnosed multiple myeloma patients enrolled in the randomized phase 2 FORTE trial.
2026
·
Mattia D'Agostino
, Giuseppe Bertuglia
, et al.
·
Journal of Clinical Oncology
·
1
Next Generation Flow and Next Generation Sequencing for Measurable Residual Disease Assessment in Multiple Myeloma Patients: A Real‐Life Italian Multicenter Harmonization Experience
2026
·
Stefania Oliva
, Marina Martello
, et al.
·
Cancer Medicine
·
1
Show more works
View as search
Works count:
48
Citation count:
554
H-index:
11
I10-index:
11
Year
Topic
Type